Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-12-10
2011-11-01
Landsman, Robert (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000, C530S388240
Reexamination Certificate
active
08048635
ABSTRACT:
Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed.
REFERENCES:
patent: 6207642 (2001-03-01), Wiley
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 6943146 (2005-09-01), Jakubowski et al.
patent: 7087725 (2006-08-01), Browning et al.
patent: 7109298 (2006-09-01), Browning et al.
patent: 7129061 (2006-10-01), Browning et al.
patent: 7169387 (2007-01-01), Rennert
patent: 7208151 (2007-04-01), Browning et al.
patent: 7482430 (2009-01-01), Wiley
patent: 7495086 (2009-02-01), Kim et al.
patent: 7507807 (2009-03-01), Wiley
patent: 7517962 (2009-04-01), Wiley
patent: 7566769 (2009-07-01), Browning et al.
patent: 2002/0015703 (2002-02-01), Rennert
patent: 2004/0176296 (2004-09-01), Holtzman et al.
patent: 2004/0203083 (2004-10-01), Buechler et al.
patent: 2006/0003932 (2006-01-01), Jakubowski et al.
patent: 2006/0240004 (2006-10-01), Burkly et al.
patent: 2006/0252122 (2006-11-01), Browning et al.
patent: 2007/0110745 (2007-05-01), Rennert
patent: 2007/0280940 (2007-12-01), Winkles et al.
patent: 2008/0008714 (2008-01-01), Browning et al.
patent: 2008/0187544 (2008-08-01), Burkly et al.
patent: 2008/0241163 (2008-10-01), Burkly et al.
patent: 2008/0279853 (2008-11-01), Burkly et al.
patent: 2008/0286271 (2008-11-01), Ashkenazi et al.
patent: 2008/0292622 (2008-11-01), Burkly et al.
patent: 2009/0068102 (2009-03-01), Burkly et al.
patent: 2009/0124993 (2009-05-01), Burkly et al.
patent: 1354950 (2003-10-01), None
patent: 1566636 (2005-08-01), None
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 00/42073 (2000-07-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 01/85193 (2001-11-01), None
patent: WO 02/22166 (2002-03-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO 03/040307 (2003-05-01), None
patent: WO 03/086311 (2003-10-01), None
patent: WO 2005/080972 (2005-09-01), None
patent: WO 2006/047172 (2006-05-01), None
patent: WO 2006/052926 (2006-05-01), None
patent: WO 2006/088890 (2006-08-01), None
patent: WO 2006/089095 (2006-08-01), None
patent: WO 2006/096487 (2006-09-01), None
patent: WO 2006/122187 (2006-11-01), None
patent: WO 2006/130374 (2006-12-01), None
patent: WO 2006/130429 (2006-12-01), None
patent: WO 2006/138219 (2006-12-01), None
patent: WO 2008/048924 (2008-04-01), None
Kawakita T, et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochemical and Biophysical Research Communications, 2004, vol. 318, p. 723-733.
Wada T, et al. Detection of urinary interleukin-8 in glomerular diseases. Kidney International, 1994, vol. 46, p. 455-460.
Saemann M, et al. Urinary tract infection in renal transplant recipients. Eur. J. Clin. Invest., 2008, vol. 38(S2), p. 58-65.
Chicheportiche, Y. et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. Journal of Biological Chemistry, 1991, vol. 272, No. 51, p. 32401-32410.
Campbell et al., “The Role of Tweak/Fn14 in the Pathogenesis of Inflammation and Systemic Autoimmunity”, Frontiers in Bioscience, vol. 9:2273-2284 (2004).
Putterman et al., “Tweak Blockade Improves Kidney Disease in Lupus-Prone Mice: A Novel Approach to the Treatment of Lupus Nephritis?”, Abstract #562.27, Fed. of Amer. Soc. For Experimental Biol., vol. 18, No. 5 (2004).
International Search Report dated Jan. 26, 2007 for international application No. PCT/US2006/022830.
Boucraut, J. et al., “Anti-TWEAK Monoclonal Antibodies Reduce CNS Immune Cell Infiltration and Severity of Experimental Autoimmune Encephalomyelitis” Meeting: Autoimmunity: Mechanisms and Novel Treatments, Mykonos, Greece, Oct. 8-13, 2003; Aegean Conference Series, vol. 12, Abstract 64, p. 89 (2003).
Campbell, S. et al., “Proinflammatory Effects of TWEAK/Fn14 Interactions in Glomerular Mesangial Cells”, J. Immunol. 176:1889-1898 (2006).
Chicheportiche, Y. et al., “Proinflammatory Activity of TWEAK on Human Dermal Fibroblasts and Synoviocytes: Blocking and Enhancing Effects of Anti-TWEAK Monoclonal Antibodies”, Arthritis Res. 4(2):126-33 (2002). Epub Nov. 9, 2001.
Desplat-Jego, S. et al., “Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis”, Clin. Immunol. 117(1):15-23 (2005).
Desplat-Jego, S. et al., “TWEAK Is Expressed by Glial Cells, Induces Astrocyte Proliferation and Increases EAE Severity”, J. Neuroimmunol. 133:116-123 (2002).
Kalled et al., “Anti-CD40 Ligand Antibody Treatment of SNF .sub.1 Mice with Established Nephritis: Preservation of Kidney Function”, J. Immunol. 160:2158-2165 (1998).
Kaplan et al., “The Apoptotic Ligands TRAIL, TWEAK, and Fas Ligand Mediate Monocyte Death Induced by Autologous Lupus T Cells”, J. Immunol. 169:6020-6029 (2002).
Mueller, A.M. et al., “Targeting fibroblast growth-factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis”, J. Neuroimmunol. 159(1-2):55-65 (2005).
Perper, S.J. et al., “TWEAK is a novel arthritogenic mediator”, J. Immunol. 177(4):2610-2620 (Aug. 15, 2006).
Potrovita, I. et al., “TWEAK—A Regulator of Neuronal Cell Death”, Naunyn-Schmiedeberg's Archives of Pharmacology 369(Suppl. 1):R12 (Mar. 9, 2004).
Rovin et al., “Urine chemokines as biomarkers of human systemic lupus erythematosus activity”, J. Am. Soc. Nephrol. 16:467-473 (2005).
Saas, P. et al., “TWEAK Stimulation of Astrocytes and the Proinflammatory Consequences”, GLIA 32(1):102-107 (2000).
U.S. Appl. No. 11/422,191 by Browning, et al., filed Jun. 5, 2006.
Zhao, Z. et al., “TWEAK/Fn14 Interactions Are Instrumental in the Pathogenesis of Nephritis in the Chronic Graft-versus-Host Model of Systemic Lupus Erythematosis”, J. Immunol. 179:7949-7958 (2007).
Burkly Linda C.
Michaelson Jennifer
Putterman Chaim
Albert Einstein College of Medicine of Yeshiva University
Biogen Idec MA Inc.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Hissong Bruce D
Landsman Robert
LandOfFree
Measurement of soluble Tweak levels for evaluation of lupus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Measurement of soluble Tweak levels for evaluation of lupus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Measurement of soluble Tweak levels for evaluation of lupus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264025